Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 17, 2004. The report is a disclosure of changes in directors' interests in the company's Ordinary Shares, specifically regarding the GlaxoSmithKline US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes within a retirement fund.
Material Changes
The primary material change reported is an increase in the number of Ordinary Share American Depositary Receipts (ADRs) held by the GlaxoSmithKline US Retirement Savings Plan. As of August 13, 2004, the fund's holdings increased from 19,162,092 to 19,226,771 shares due to a movement in the fund.
Outlook, Risks, and Commentary
The filing notes that the Retirement Savings Plan is a discretionary fund for current and former employees. Two directors, Dr. J.P. Garnier and Dr. T. Yamada, are potentially interested in the shares held in the fund in the same manner as other employees. No specific guidance, risks, or unusual items regarding company operations are disclosed in this text.
Key Facts for Investor Verification
- Shareholding Change: The US Retirement Savings Plan increased its ADR holdings by 64,679 shares.
- Transaction Price: The average price for the movement was $39.25 per share.
- Director Involvement: Directors Dr. J.P. Garnier and Dr. T. Yamada have potential interests in the fund's holdings.
- Reporting Date: The change was notified to the company on August 16, 2004, and reported on August 17, 2004.